A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures
A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chiba, Japan
-
Fukuoka, Japan
-
Gihu, Japan
-
Hiroshima, Japan
-
Kagoshima, Japan
-
Kobe, Japan
-
Kyoto, Japan
-
Miyazaki, Japan
-
Nagaoka, Japan
-
Niigata, Japan
-
Okayama, Japan
-
Osaka, Japan
-
Shizuoka, Japan
-
Tokyo, Japan
-
Toyama, Japan
-
Yamagata, Japan
-
-
Aichi
-
Aichi-gun, Aichi, Japan
-
Nagoya, Aichi, Japan
-
Nayoga, Aichi, Japan
-
-
Aomori
-
Hirosaki, Aomori, Japan
-
-
Fukuoka
-
Kitakyusyu, Fukuoka, Japan
-
Kurume, Fukuoka, Japan
-
-
Hiroshima
-
Fukuyama, Hiroshima, Japan
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan
-
Hakodate, Hokkaido, Japan
-
Sapporo, Hokkaido, Japan
-
-
Hyogo
-
Kobe, Hyogo, Japan
-
-
Ishikawa
-
Kahoku-gun, Ishikawa, Japan
-
-
Kumamoto
-
Kikuchi-gun, Kumamoto, Japan
-
-
Miyagi
-
Sendai, Miyagi, Japan
-
-
Nagasaki
-
Omura, Nagasaki, Japan
-
-
Osaka
-
Izumi, Osaka, Japan
-
Neyagawa, Osaka, Japan
-
Suita, Osaka, Japan
-
-
Tochigi
-
Kawachi-gun, Tochigi, Japan
-
-
Tokyo
-
Kodaira, Tokyo, Japan
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Epileptic patients who fulfill the following criteria are eligible for inclusion in the study:
- Subjects aged from 16 to 65 years at the acquisition of informed consent to the trial participation
- Seizure type: subjects with epileptic seizures which were diagnosed as partial seizures more than 2 years ago according to "Clinical and electroencephalographic classification of epileptic seizures (1981)" defined by the International League Against Epilepsy (ILAE) and confirmed with an EEG that has been performed within 1 year before Screening or at the Screening Visit
- Subjects whose previous therapy before screening involved at least two standard anti-epileptic drugs (AEDs) for partial seizures, and in whom it can be confirmed that the doses met the daily dose specified for the treatment of epilepsy in the package insert and that the therapy has been continued for at least 3 months
- Frequency of epileptic seizures: subjects experiencing partial seizures at least 12 times in 12 weeks during the Baseline Period (Week -12 to Week 0) and at least twice in every 4 weeks
Exclusion Criteria:
The following patients are not eligible for inclusion into the study:
- Subjects who were diagnosed with status epilepticus within 3 months before screening
- Subjects with no partial seizures of which frequency was measured during the Baseline Period
- Subjects who underwent surgery for epilepsy within 2 years before Screening or who were scheduled to undergo brain surgery during the study period and within 4 weeks after the completion of this study
- Subjects with a history of oral treatment with Levetiracetam (LEV)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lev 0.5 g
Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
|
Other Names:
|
|
Experimental: Lev 1 g
Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
|
Other Names:
Other Names:
|
|
Experimental: Lev 2 g
Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
|
Other Names:
Other Names:
|
|
Experimental: Lev 3 g
Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
|
Other Names:
Other Names:
|
|
Placebo Comparator: Placebo
Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period
Time Frame: From Baseline to the 12-week Evaluation Period
|
From Baseline to the 12-week Evaluation Period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Partial (Type I) seizure frequency per week over the Evaluation Period
Time Frame: 12-week Evaluation Period
|
12-week Evaluation Period
|
|
Partial (Type I) seizure responder rates (50 %, 75 %) over the Evaluation Period
Time Frame: From Baseline to the 12-week Evaluation Period
|
From Baseline to the 12-week Evaluation Period
|
|
Seizure freedom over the Evaluation Period
Time Frame: 12-week Evaluation Period
|
12-week Evaluation Period
|
|
Categorized percentage reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period
Time Frame: From Baseline to the 12-week Evaluation Period
|
From Baseline to the 12-week Evaluation Period
|
|
Percentage reduction from Baseline in seizure frequency per week by seizure subtype (IA, IB, IC, IA + IB, other) over the Evaluation Period
Time Frame: From Baseline to the 12-week Evaluation Period
|
From Baseline to the 12-week Evaluation Period
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- N01221
- 2014-004333-57 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.